What kind of biotech startup wins a $3B syndicate, woos a gallery of marquee scientists and recruits GSK's Hal Barron as CEO in a stunner? Let Rick Klausner explain
Endpoints News
50.5K posts
Endpoints News
@endpts
The biopharma world is here. Get the industry’s most comprehensive daily news reports at endpts.com/subscribe
- 🚨 The FDA's Peter Marks has resigned, after disagreeing with HHS Secretary Robert F. Kennedy Jr. over Kennedy's anti-vaccine policies. In a scathing letter, Marks criticized Kennedy for what he called "misinformation and lies"
- 🚨 BREAKING: Vinay Prasad, FDA's controversial head of vaccines and biologics, is out
- Exclusive: Vertex is pulling back on its genetic medicine research, ending all work related to adeno-associated viruses, or AAVs
- Last month, DeepMind released a specialized version of the original AlphaFold software for predicting protein-protein complexes. The new approach could help unlock insights into the underlying process behind a wide range of diseases.
- Scott Gottlieb on what it would take to compete with China's biotech rise
- For the first time, completely designed — or “de novo,” meaning from the beginning — proteins are being tested in clinical trials, perhaps most notably as a cancer immunotherapy invented in David Baker’s lab and developed by a spinout.
- Arcadia will study a selection of so-called non-model organisms: the literally trillions of organisms that are rarely studied in labs because they’re difficult to manipulate or don’t obviously translate to humans.
- Just a few short months after Altos Labs made its debut flush with $3 billion in cash, a famous CEO and a star-studded scientific team, the cellular rejuvenation biotech may now be seeing the first inklings of a competitor: Genentech.
- David Liu, the co-inventor of base editing and co-founder of Beam Therapeutics, unveiled a new approach for using CRISPR to turn patients’ sickling hemoglobin into a healthy form of the protein.
- Vertex and CRISPR Therapeutics showed their experimental therapy kept two sickle patients from experiencing painful incidences and kept patients with another blood disorder from requiring transfusions. endpts.com/vertex-looking…
- Novartis is buying gene therapy and neuroscience biotech Kate Therapeutics in a deal worth $1.1 billion.
- Breaking: In a world first, Vertex, CRISPR win UK approval for CRISPR-edited therapy to treat sickle cell disease, beta-thalassemia
- During #DrugDiscoveryDay @RLCscienceboss had an in-depth discussion with @arenabioworks co-founder @SchreiberStuart around small molecule drug discovery, AI in chemical biology, & new models of funding science. Watch this conversation & more On Demand: bit.ly/44503Ak
00:00
